Dr. David Reardon explains the basics of immunotherapy at our Immunotherapy Patient Summit in Boston on July 27, 2019. www.cancerresearch.org/summit #CRIsummit
David Reardon, M.D., serves as clinical director at Dana-Farber Cancer Institute's Center for Neuro-Oncology and is a professor at Harvard Medical School. He specializes in brain cancers, such as glioblastoma.
On Saturday, July 27, 2019, the Cancer Research Institute brought its Immunotherapy Patient Summit to Boston for the first time, taking place at the Dana-Farber Cancer Institute (DFCI), one of the world’s foremost cancer treatment centers.
The 2019 CRI Immunotherapy Summit in Boston was held at Dana-Farber Cancer Institute on July 27, 2019. Cancer Research Institute Immunotherapy Patient Summits are free half-day Saturday events that provide a forum for patients, caregivers, and advocates to meet together along with scientific and healthcare experts to learn more about how new breakthroughs in immunotherapy are changing standards of care for all cancers. Register at www.cancerresearch.org/summit
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system's power to control and potentially cure all cancers. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field's leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. Our Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. www.cancerresearch.org